Novakand Pharma announces AGM results on 25 May 2026
The meeting approved financial statements, decided to retain earnings, and elected new board members including Michael Zell as chairman.
See the latest news and media coverage for Novakand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of innovative drugs for inflammation and cancer
novakand.comLast updated
In short: Novakand Pharma was delisted from Nasdaq First North, revamped its board, and pivoted to its fractalkine program after a merger deal collapsed.
The meeting approved financial statements, decided to retain earnings, and elected new board members including Michael Zell as chairman.
The documents are available on the company's website.
The annual general meeting is held on May 25, 2026 in Stockholm. Registration is required by May 19. Agenda includes annual report, discharge from liability and elections.
The meeting decides on focus on fractal kinase program, capital needs and special review of CEO, board and capital usage. The board makes seats available.
Novakand Pharma AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate...
Background Novakand Pharma AB (”Novakand” or the ”Company”) announced on February 24, 2026, that Nasdaq had rejected Novakand's application for continued listing on First North...
KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of...
On November 25, 2025, the shares in Novakand Pharma AB (the "Company") were given observation status with reference to the Company's disclosure of its interim...
Track Novakand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novakand Pharma and other trending companies.